In vitro metabolism of alectinib, a novel potent ALK inhibitor, in human: contribution of CYP3A enzymes

References

• Ajimizu H, Kim YH, Mishima M. (2015). Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib. Med Oncol 32:477.
   PubMed Web of Science ®Google Scholar
• Avrillon V, Perol M. (2017). Alectinib for treatment of ALK-positive non-small-cell lung cancer. Future Oncol 13:321–35.
   PubMed Web of Science ®Google Scholar
• Baneyx G, Fukushima Y, Parrott N. (2012). Use of physiologically based pharmacokinetic modeling for assessment of drug-drug interactions. Future Med Chem 4:681–93.
   PubMed Web of Science ®Google Scholar
• Choi YL, Takeuchi K, Soda M, et al. (2008). Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer. Cancer Res 68:4971–6.
   PubMed Web of Science ®Google Scholar
• Chun SG, Choe KS, Iyengar P, et al. (2012). Isolated central nervous system progression on Crizotinib: an Achilles heel of non-small cell lung cancer with EML4-ALK translocation? Cancer Biol Ther 13:1376–83.
   PubMed Web of Science ®Google Scholar
• Cleary Y, Gertz M, Morcos PN, et al. (2017). Physiologically-based pharmacokinetic (PBPK) modeling to evaluate drug-drug interaction (DDI) risk of alectinib. Clin Pharmacol Ther 101, S40.
   Web of Science ®Google Scholar
• Costa DB, Kobayashi S, Pandya SS, et al. (2011). CSF concentration of the anaplastic lymphoma kinase inhibitor crizotinib. J Clin Oncol 29:e443–5.
   PubMed Web of Science ®Google Scholar
• Dalvie D, Obach RS, Kang P, et al. (2009). Assessment of three human in vitro systems in the generation of major human excretory and circulating metabolites. Chem Res Toxicol 22:357–68.
   PubMed Web of Science ®Google Scholar
• De Brabanter N, Esposito S, Tudela E, et al. (2013). In vivo and in vitro metabolism of the synthetic cannabinoid JWH-200. Rapid Commun Mass Spectrom 27:2115–26.
   PubMed Web of Science ®Google Scholar
• Denissen JF, Grabowski BA, Johnson MK, et al. (1994). The orally active renin inhibitor A-74273. In vivo and in vitro morpholine ring metabolism in rats, dogs, and humans. Drug Metab Dispos 22:880–8.
   PubMed Web of Science ®Google Scholar
• Gadgeel SM, Gandhi L, Riely GJ, et al. (2014). Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study. Lancet Oncol 15:1119–28.
   PubMed Web of Science ®Google Scholar
• Garattini E, Terao M. (2012). The role of aldehyde oxidase in drug metabolism. Expert Opin Drug Metab Toxicol 8:487–503.
   PubMed Web of Science ®Google Scholar
• Gordi T, Tan LH, Hong C, et al. (2003). The pharmacokinetics of linezolid are not affected by concomitant intake of the antioxidant vitamins C and E. J Clin Pharmacol 43:1161–7.
   PubMed Web of Science ®Google Scholar
• Horn L, Pao W. (2009). EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 27:4232–5.
   PubMed Web of Science ®Google Scholar
• Kinoshita K, Asoh K, Furuichi N, et al. (2012). Design and synthesis of a highly selective, orally active and potent anaplastic lymphoma kinase inhibitor (CH5424802). Bioorg Med Chem 20:1271–80.
   PubMed Web of Science ®Google Scholar
• Kodama T, Tsukaguchi T, Yoshida M, et al. (2014). Selective ALK inhibitor alectinib with potent antitumor activity in models of crizotinib resistance. Cancer Lett 351:215–21.
   PubMed Web of Science ®Google Scholar
• Koivunen JP, Mermel C, Zejnullahu K, et al. (2008). EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clinical Cancer Res 14:4275–83.
   PubMed Web of Science ®Google Scholar
• Kwak EL, Bang YJ, Camidge DR, et al. (2010). Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 363:1693–703.
   PubMed Web of Science ®Google Scholar
• Maeda M, Hasumura Y, Takeuchi J. (1988). Localization of cytoplasmic and mitochondrial aldehyde dehydrogenase isozymes in human liver. Lab Invest 59:75–81.
   PubMed Web of Science ®Google Scholar
• McKillop D, Hutchison M, Partridge EA, et al. (2004a). Metabolic disposition of gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, in rat, dog and man. Xenobiotica 34:917–34.
   PubMed Web of Science ®Google Scholar
• McKillop D, McCormick AD, Miles GS, et al. (2004b). In vitro metabolism of gefitinib in human liver microsomes. Xenobiotica 34:983–1000.
   PubMed Web of Science ®Google Scholar
• Morcos PN, Cleary Y, Guerini E, et al. (2017a). Clinical drug-drug interactions through cytochrome P450 3A (CYP3A) for the selective ALK inhibitor alectinib. Clin Pharmacol Drug Dev 6:280–91.
   PubMed Web of Science ®Google Scholar
• Morcos PN, Yu L, Bogman K, et al. (2017b). Absorption, distribution, metabolism and excretion (ADME) of the ALK inhibitor alectinib: results from an absolute bioavailability and mass balance study in healthy subjects. Xenobiotica 47:217–29.
   PubMed Web of Science ®Google Scholar
• Oda S, Fukami T, Yokoi T, Nakajima M. (2015). A comprehensive review of UDP-glucuronosyltransferase and esterases for drug development. Drug Metab Pharmacokinet 30:30–51.
   PubMed Web of Science ®Google Scholar
• Ou SH, Ahn JS, De Petris L, et al. (2016). Alectinib in crizotinib-refractory ALK-rearranged non-small-cell lung cancer: a phase II global study. J Clin Oncol 34:661–8.
   PubMed Web of Science ®Google Scholar
• Rodrigues AD. (1999). Integrated cytochrome P450 reaction phenotyping: attempting to bridge the gap between cDNA-expressed cytochromes P450 and native human liver microsomes. Biochem Pharmacol 57:465–80.
   PubMed Web of Science ®Google Scholar
• Sakamoto H, Tsukaguchi T, Hiroshima S, et al. (2011). CH5424802, a selective ALK inhibitor capable of blocking the resistant gatekeeper mutant. Cancer Cell 19:679–90.
   PubMed Web of Science ®Google Scholar
• Sato-Nakai M, Kawashima K, Nakagawa T, et al. (2017). Metabolites of alectinib in human: their identification and pharmacological activity. Heliyon, in press.
   Google Scholar
• Shaw AT, Gandhi L, Gadgeel S, et al. (2016). Alectinib in ALK-positive, crizotinib-resistant, non-small-cell lung cancer: a single-group, multicentre, phase 2 trial. Lancet Oncol 17:234–42.
   PubMed Web of Science ®Google Scholar
• Shinmura K, Kageyama S, Tao H, et al. (2008). EML4-ALK fusion transcripts, but no NPM-, TPM3-, CLTC-, ATIC-, or TFG-ALK fusion transcripts, in non-small cell lung carcinomas. Lung Cancer 61:163–9.
   PubMed Web of Science ®Google Scholar
• Slatter JG, Adams LA, Bush EC, et al. (2002). Pharmacokinetics, toxicokinetics, distribution, metabolism and excretion of linezolid in mouse, rat and dog. Xenobiotica 32:907–24.
   PubMed Web of Science ®Google Scholar
• Soda M, Choi YL, Enomoto M, et al. (2007). Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 448:561–6.
   PubMed Web of Science ®Google Scholar
• Sodhi JK, Wong S, Kirkpatrick DS, et al. (2015). A novel reaction mediated by human aldehyde oxidase: amide hydrolysis of GDC-0834. Drug Metab Dispos 43:908–15.
   PubMed Web of Science ®Google Scholar
• Stanulovic M, Chaykin S. (1971). Metabolic origins of the pyridones of N 1 - methylnicotinamide in man and rat. Arch Biochem Biophys 145:35–42.
   PubMed Web of Science ®Google Scholar
• Swaisland HC, Cantarini MV, Fuhr R, Holt A. (2006). Exploring the relationship between expression of cytochrome P450 enzymes and gefitinib pharmacokinetics. Clin Pharmacokinet 45:633–44.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Choi YL, Soda M, et al. (2008). Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts. Clin Cancer Res 14:6618–24.
   PubMed Web of Science ®Google Scholar
• Takeuchi K, Choi YL, Togashi Y, et al. (2009). KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 15:3143–9.
   PubMed Web of Science ®Google Scholar
• Volotinen M, Turpeinen M, Tolonen A, et al. (2007). Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug Metab Dispos 35:1135–41.
   PubMed Web of Science ®Google Scholar
• Wong DW, Leung EL, So KK, et al. (2009). The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS. Cancer 115:1723–33.
   PubMed Web of Science ®Google Scholar
• Wu WN, Mutter MS. (1995). Biotransformation of linogliride, a hypoglycemic agent in laboratory animals and humans. J Pharm Biomed Anal 13:857–67.
   PubMed Web of Science ®Google Scholar
• Yang Y, Wu K, Yuan H, Yu M. (2009). Cytochrome oxidase 2D6 gene polymorphism in primary open-angle glaucoma with various effects to ophthalmic timolol. J Ocul Pharmacol Ther 25:163–71.
   PubMed Web of Science ®Google Scholar
• Zientek MA, Youdim K. (2015). Reaction phenotyping: advances in the experimental strategies used to characterize the contribution of drug-metabolizing enzymes. Drug Metab Dispos 43:163–81.
   PubMed Web of Science ®Google Scholar
• Zorzano A, Herrera E. (1990). Differences in kinetic characteristics and in sensitivity to inhibitors between human and rat liver alcohol dehydrogenase and aldehyde dehydrogenase. Gen Pharmacol 21:697–702.
   PubMedGoogle Scholar